OAV101 for bulbo-spinal atrophy, x-linked

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 21 Apr 2021: Trial registered, NCT04851873
  2. 8 Sep 2021: Trial started, NCT04851873
  3. 11 Oct 2021: Trial registered, NCT05073133
  4. 4 Nov 2021: Trial started, NCT05073133

The trials

NCT04851873: Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

State
Completed
Phase
Phase 3
People
24 taking part
Started
8 Sep 2021
Primary completion
13 Jun 2023
Arms
OAV101
Results
Posted on the registry
  1. 21 Apr 2021: Trial registered
  2. 8 Sep 2021: Trial started
  3. 13 Jun 2023: Trial completed
  4. 5 Jan 2024: Trial results posted

NCT05073133: Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)

State
Completed
Phase
Phase 4
People
16 taking part
Started
4 Nov 2021
Primary completion
8 Aug 2023
Arms
OAV101
Results
Posted on the registry
  1. 11 Oct 2021: Trial registered
  2. 4 Nov 2021: Trial started
  3. 8 Aug 2023: Trial completed
  4. 31 May 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.